Relationship between anti-inflammatory therapy and hepatobiliary abnormalities in cystic fibrosis patients

被引:0
作者
Pukhalsky, Alexander [1 ]
Shmarina, Galina [1 ]
Kashirskaya, Natalia [1 ]
Perederko, Liudmila [1 ]
Kapranov, Nikolai [1 ]
机构
[1] Res Ctr Med Genet, Dept Cyst Fibrosis, Moscow 115478, Russia
来源
MULTIDISCIPLINARY RESPIRATORY MEDICINE | 2009年 / 4卷 / 04期
关键词
Azithromycin; cystic fibrosis; glucocorticoids; hepatobiliary abnormalities; inflammation; LUNG-DISEASE; INFLAMMATION;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Anti-inflammatory therapy is a frequent but not obligatory component of cystic fibrosis (CF) lung disease treatment. The aim of this investigation was to compare the frequency of hepatobiliary abnormalities, the most common CF complication, in patients treated with anti-inflammatory drugs and those who did not receive anti-inflammatory treatment. This study involved a review of hospital medical records of CF patients (n = 183) younger than 19 years. Ninety-six patients were treated with basic therapy only and 87 individuals received besides basic therapy anti-inflammatory treatment with azithromycin (AZ; 48 patients) or prednisolone (PD; 39 patients) in the form of alternated course (0.3-0.5 mg/kg body weight every other day). Plasma levels of ACTH and cytokines (tumor necrosis factor-alpha, interferon-gamma, interleukin-10, transforming growth factor-beta 1) in CF patients were compared with those in healthy children. A lower frequency of hepatobiliary abnormalities in the subjects treated with PD or AZ compared to patients without anti-inflammatory therapy (WAT) was found. Cirrhosis was diagnosed in 38 of 96 WAT patients whereas only 7 of 39 (p = 0.007) and 4 of 48 (p = 0.01) children treated with PD and AZ, respectively, demonstrated such abnormality. Among 38 WAT patients with cirrhosis 24 demonstrated ultrasound changes, 11 portal hypertension, and 3 biliary cirrhosis. All studied CF patients revealed the same tendencies to change in ACTH and blood cytokine levels with the exception of interleukin-10, which was significantly higher in WAT patients than in normal children and anti-inflammatory drug treated CF individuals. In conclusion, anti-inflammatory therapy restores inflammation control and reduces the frequency of hepatobiliary abnormalities in CF patients.
引用
收藏
页码:248 / 253
页数:6
相关论文
共 50 条
  • [21] Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic Fibrosis
    Tarique, Abdullah A.
    Tuladhar, Neeraj
    Kelk, Dean
    Begum, Nelufa
    Lucas, Richard M.
    Luo, Lin
    Stow, Jennifer L.
    Wainwright, Claire E.
    Bell, Scott C.
    Sly, Peter D.
    Fantino, Emmanuelle
    CELLS, 2024, 13 (02)
  • [22] Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
    Sheikh, Zara
    Ong, Hui Xin
    Pozzoli, Michele
    Young, Paul M.
    Traini, Daniela
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (01): : 69 - 84
  • [23] Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis
    Perrem, Lucy
    Ratjen, Felix
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [24] Levels of pro- and anti-inflammatory cytokines in cystic fibrosis patients with or without gingivitis
    Duruel, Onurcem
    Berker, Ezel
    Ozsin-Ozler, Cansu
    Gharibzadeh-Hizal, Mina
    Gurpinar, Oznur
    Eryilmaz-Polat, Sanem
    Ataman-Duruel, Emel Tugba
    Tan, Cagman
    Karabulut, Erdem
    Tekcicek, Meryem
    Eser, Ozgen Koseoglu
    Kiper, Nural
    Tezcan, Ilhan
    CYTOKINE, 2020, 127
  • [25] Hepatobiliary disease in patients with cystic fibrosis
    Moyer, Katie
    Balistreri, William
    CURRENT OPINION IN GASTROENTEROLOGY, 2009, 25 (03) : 272 - 278
  • [26] Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line
    Sheikh, Zara
    Bradbury, Peta
    Reekie, Tristan A.
    Pozzoli, Michele
    Robinson, Paul D.
    Kassiou, Michael
    Young, Paul M.
    Ong, Hui Xin
    Traini, Daniela
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 902
  • [27] Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis
    Konstan, MW
    Davis, PB
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (11) : 1409 - 1423
  • [28] Relationship between a pro- and anti-inflammatory cytokine imbalance and depression in haemodialysis patients
    Taraz, Mohammad
    Khatami, Mohammad-Reza
    Gharekhani, Afshin
    Abdollahi, Alireza
    Khalili, Hossein
    Dashti-Khavidaki, Simin
    EUROPEAN CYTOKINE NETWORK, 2012, 23 (04) : 179 - 186
  • [29] Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
    Mitri, Christie
    Xu, Zhengzhong
    Bardin, Pauline
    Corvol, Harriet
    Touqui, Lhousseine
    Tabary, Olivier
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [30] Development and in vitro characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis
    Sheikh, Zara
    Dos Reis, Larissa Gomes
    Bradbury, Peta
    Meneguzzo, Giulio
    Scalia, Santo
    Young, Paul M.
    Ong, Hui Xin
    Traini, Daniela
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 596